From Financial Modeling Prep.: 2025-03-14 14:00:04

Genmab A/S, listed as NASDAQ:GMAB, is a biotech company focusing on innovative antibody therapeutics since 1999. Headquartered in Copenhagen, Denmark, Genmab aims to impact cancer and other diseases by 2030 through advanced antibody technology platforms.

Genmab adheres to Market Abuse Regulation by disclosing share transactions of managerial employees and closely associated persons to maintain investor trust and comply with regulations.

Analysts have shown positive interest in Genmab’s stock, with William Blair upgrading GMAB to Outperform on March 10, 2025, at $21.98. Asthika Goonewardene set a price target of $45, indicating a potential 77.89% increase from the then price of $20.26.

GMAB is currently trading at $20.52, up by 2.81% with a $0.56 change. The stock fluctuated between $20.52 and $21.07 today, reaching a high of $31.02 and a low of $18.64 in the past year. Genmab’s market cap is around $13.04 billion, with a trading volume of 652,900 shares on NASDAQ.



Read more at Financial Modeling Prep.:: Genmab A/S (NASDAQ:GMAB) Sees Positive Analyst Att…